期刊
EUROPEAN JOURNAL OF HEART FAILURE
卷 17, 期 9, 页码 884-892出版社
WILEY
DOI: 10.1002/ejhf.319
关键词
Heart failure; Ageing; Asia; Prevention
资金
- Bayer Yakuhin, Ltd (Osaka, Japan)
- Daiichi Sankyo Co., Ltd (Tokyo, Japan)
- Novartis Pharma K.K. (Tokyo, Japan)
- Kyowa Hakko Kirin Co., Ltd (Tokyo, Japan)
- Kowa Pharmaceutical Co., Ltd (Tokyo, Japan)
- Dainippon Sumitomo Pharma, Co., Ltd (Osaka, Japan),
- Nippon Boehringer Ingelheim Co., Ltd (Tokyo, Japan)
Heart failure (HF) is epidemic in healthcare worldwide, including Asia. It appears that HF will become more serious in the near future, with the epidemiological transition and ageing of the population. However, in contrast to Western countries, information on HF epidemiology is still limited in Asia, particularly in South Asia. In this review, we will briefly summarize available information regarding the current and future burden of HF in Asia, which indicates the importance of both primary prevention of underlying diseases of HF and secondary prevention, including management of ischaemic HF, HF with preserved EF, and HF in the elderly.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据